Intensive insulin therapy and pentastarch resuscitation in severe sepsis;Die VISEP-studie: Ein schritt vorwärts, zwei schritte zurück

Intensivmedizin und Notfallmedizin

Volumn 45, Issue 5, 2008, Pages 255-262

  Engelmann, Lothar ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Hydroxyethyl starch; Hypoglycemia; Intensive insulin therapy; Mortality; Renal failure; Ringer's lactate; Septic shock; Severe sepsis; Volume resuscitation

Indexed keywords

EID: 45849099796     PISSN: 01753851     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00390-008-0887-x     Document Type: Review

References (41)

1. Van den Berghe G, Wouters P, Weekers F et al (2001) Intensive insulin therapy in critically ill patients. N Engl J Med 345:1359-1367
2. Van den Berghe G, Wilmer A, Hermans G et al (2006) Intensive insulin therapy in the medical ICU. N Engl J Med 354:449-461
3. Van den Berghe G, Wouters PJ, Bouillon R et al (2003) Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 31:359-366
4. Ellger B, Westphal M, Stubbe H et al (2008) Blutzuckerkontrolle bei Patienten mit Sepsis und septischem Schock - Freund oder Feind? Anästhesist 57:43-48
5. Krinsley JS (2004) Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 79:992-1000
6. Christiansen C, Toft P, Jorgensen HS et al (2004) Hyperglycaemia and mortality in critically ill patients. A prospective study. Intensive Care Med 30:1685-1688
7. Kanji S, Singh A, Tierney M et al (2004) Standardization of intravenous insulin therapy improves the efficiency and safety of blood glucose control in critically ill adults. Intensive Care Med 30:804-810
8. Meijering S, Corstjens AM, Tulleken JE et al (2006) Towards a feasible algorithm for tight glycaemic control in critically ill patients: a systematic review of the literature. Critical Care 10:R19
9. Barclay L, Vega C, Martin BN (2008) Intensive insulin therapy may protect renal function in critically ill patients. J Am Soc Nephrol, published online January 30
10. Asakawa H, Miyagawa JI, Hanafusa T et al (1997) High glucose and hyperosmolarity increase secretion of interleukin- 1β in cultured human aortic endothelial cells. J Diab Comp 11:176-179
11. Nemeth ZH, Deitch EA, Szabo C, Hasko G (2002) Hyperosmotic stress induces nuclear factor-κB activation and interleukin-8 production in human intestinal epithelial cells. Am J Pathol 161:877-996
12. Perner A, Nielsen SE, Rask-Madsen J (2003) High glucose impairs superoxide production from isolated blood neutrophils. Intensive Care Med 29:642-645
13. McGinn S, Poronnik P, King M et al (2003) High glucose and endothelial cell growth: novel effects independent of autocrine TGF-β1 and hyperosmolarity. Am J Physiol Cell Physiol 284:C1374-C1386
14. Marik PE, Raghavan M (2004) Stresshyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med 30:748-756
15. Van den Berghe G (2004) How does blood glucose control with insulin save lives in intensive care? J Clin Invest 114:1187-1195
16. Jeschke MG, Klein D, Herndon DN (2004) Insulin treatment improves the systemic inflammatory reaction to severe trauma. Ann Surg 239:553-560
17. Dandona P, Mohanty P, Chaudhuri A et al (2005) Insulin infusion in acute illness. J Clin Invest 115:2069-2072
18. Langouche L, Vanhorebeek I, Vlasserelaers D, Perre SV et al (2005) Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest 115:2277-2286
19. Dandona P, Aljada A, Mohanty P et al (2001) Insulin inhibits intranuclear nuclear factor _B and stimulates IκB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 86:3257-3265
20. Zander R, Boldt J, Engelmann L et al (2007) Studienprotokoll der VISEPStudie. Eine kritische Stellungnahme. Anästhesist 56:71-77
21. Brunkhorst FM, Werdan K (2006) Intensivmedizin - Nach den positiven Studien kommen die Fragen. Dtsch med Wochenschr 131:1441-1444
22. Rivers E, Nguyen B, Havstad S et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368-1377
23. Köhler H, Zschiedrich H, Clasen R et al (1982) Blutvolumen, kolloidosmotischer Druck und Nierenfunktion von Probanden nach Infusion mittelmolekularer 10% Hydroxyäthylstärke 200/0,5 und 10% Dextran 40. Anästhesist 31:61-67
24. Reinhart K (2006) Fluid therapy in sepsis - VISEP study results (SepNet). Symposium Intensivmedizin, Bremen
25. Lehmann GB, Asskali F, Boll M et al (2007) HES 130/0,42 shows less alteration of pharmacokinetics than HES 200/0.5 when dosed repeatedly. Br J Anaesth 98:635-644
26. Schortgen F, Lacherade JC, Bruneel F et al (2001) Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomized study. Lancet 357:911-916
27. Wiedermann CJ (2004) Hydroxyethyl starch - can the safety problem be ignored? Wien Klin Wochenschr 116/17/18:583-594
28. Boldt J, Brosch C, Ducke M et al (2007) Influence of volume therapy with modern hydroxyethylstarch preparation on kidney function in cardiac surgery patients with compromised renal function: a comparison with human albumin. Crit Care Med 35:2740-2746
29. Sakr Y, Payen D, Reinhart K et al (2007) Effects of hydroxyethyl starch administration on renal function in critically ill patients. Br J Anaesth 98:216-224
30. Brunkhorst FM, Schortgen F, Sakr Y, Vincent JL (2007) Effects of hydroxyethyl starch in critically ill patients. Br J Anaesth 98:842-844
31. Lang W (2007) Treffpunkt Stewart. Pufferbasen,.,base excess" und starke Ionen. Anästhesist 56:388-397
32. Adams HA (2007) Hämodilution und Infusionstherapie bei hypovolämischen Schock. Anästhesist 56:371-379
33. Kellum JA, Song M, Almasri E (2006) Hyperchloremic acidosis increases circulating inflammatory molecules in experimental sepsis. CHEST 130:962-967
34. Hoffmann JN, Vollmar B, Laschke MW et al (2002) Hydroxyethyl starch (130 kD), but not crystalloid volume support, improves microcirculation during normotensive endotoxemia. Anaesthesiology 97:460-470
35. Collis RE, Collins PW, Gutteridge CN et al (1994) The effect of hydroxyethyl starch and other plasma volume substitutes on endothelial cell activation; an in vitro study. Intensive Care Med 20:37-41
36. Boldt J (2006) Do plasma substitutes have additional properties beyond correcting volume deficits? SHOCK 25:103-116
37. Dieterich HJ, Weissmüller T, Rosenberger P, Eltzschig HK (2006) Effect of hydroxyethyl starch on vascular leak syndrome and neutrophil accumulation during hypoxia. Crit Care Med 34:1775-1782
38. Dieterich HJ, Nohe B, Drescher N et al (1998) Modulation von Phagozytose und Endothelfunktion. Anästhesiol Intensivmed Notfallmed Schmerzther 33:270-274
39. Boldt J, Müller M, Menges T et al (1996) Influence of different volume therapy regimens on regulators of the circulation in the critically ill. Br J Anaesth 77:480-487
40. Hofbauer R, Moser D, Hornykiewicz S et al (1999) Hydroxyethyl starch reduces the chemotaxis of white cells through endothelial cell monolayers. Transfusion 39:289-294
41. Schmand JF, Ayala A, Morrison MH, Chaudry IH (1995) Effects of hydroxyethyl starch after trauma-hemorrhagic shock: restoration of macrophage integrity and prevention of increased circulating interleukin-6 levels. Crit Care Med 23:806-814